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androgen synthesis. In a preplanned interim analysis of the Phase 3 trial COU-
AA-301, AA plus prednisone (P) showed a significant overall survival (OS) benefit 
of 3.9 months vs placebo plus P (de Bono, NEJM 2011). A preplanned and updated 
analysis showed that the improvement in median OS increased from 3.9 months 
to 4.6 months (HR = 0.74) (Fizazi, Lancet Oncol 2012). The purpose of this study 
was to evaluate the cost effectiveness of AA vs P using data from Swedish 
patients. METHODS: A survival-based decision analysis model was developed 
incorporating 3 health states: progression-free survival, post-progression 
survival, and OS (indirect comparison). The cost-effectiveness model was 
populated with data from one placebo-controlled randomized clinical trial in 
which AA was an add-on to P (de Bono, NEJM 2011), and treatment duration from 
the name-patient-programme (NPP) in Sweden for patients with metastatic 
castrate-resistant prostate cancer post-docetaxel. Resource utilization and costs 
reflected Swedish treatment conditions within a broad societal perspective. Drug 
costs per 3-week-model-cycle were $3180 (€2300) and $53 (€41) for AA and P, 
respectively. RESULTS: Total costs per patient were $85270 (€67300) and $52700 
(€41600) for AA and P, respectively. Quality-adjusted life years (QALYs) were 1.24 
and 0.77 for AA and P, respectively. CONCLUSIONS: The results show that AA 
treatment compared to P has a cost per QALY gained of $69800 (€55000). AA 
provides an OS benefit with a highly manageable and benign safety profile, 
compared to P, which has negligible effects on OS and QoL.  
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OBJECTIVES: Approximately 2.8 million American men have a history of prostate 
cancer, the most prevalent cancer among men in the US. This study quantified 
the effects of prostate cancer on direct health care costs to insurers and patients. 
METHODS: Using data 1996-2009 from the Medical Expenditure Panel Survey 
(MEPS), a large, nationally-representative database from the US, this study 
performed multivariate analyses of the relationship between prostate cancer and 
direct annual health care costs to insurers and patients, at individual and US 
aggregate levels. All men age 40 and older with International Classification of 
Disease Codes, 9th revision of 185 were identified. RESULTS: The MEPS database 
included 1,399 patients with prostate cancer. Mean age was 72 years, and 71% 
were Caucasian. Prostate cancer patients incurred $9,300 more in overall annual 
health care costs per patient when compared to non-prostate cancer patients 
($18,423 vs. $9,093). The majority of direct health care costs were borne by the 
insurer ($8,900) rather than the patient ($430). Prostate cancer had a larger effect 
on incremental costs for younger patients ($16,253 40-64 years vs. $10,236 65-74 
years; $7,767 75+ years). When aggregated to the US population, prostate cancer 
accounted for an incremental annual cost of $14.27 billion. The largest aggregate 
costs were incurred by patients aged 40-64 years ($5.33 billion), compared to 
those aged 65-74 ($4.86 billion) and patients aged 75+ ($4.08 billion). 
CONCLUSIONS: These findings indicate that the cost burden from prostate 
cancer is quite large. Younger patients incur more direct health care costs, 
possibly due to more aggressive treatment practices, which may be related to 
more aggressive tumor burden. With aging of the population, prevalence of 
prostate cancer is expected to increase to 3.2 million in the US in 2020. Further 
research to understand these cost implications is warranted.  
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OBJECTIVES: In terms of indirect cost, prostate cancer appears to have an 
adverse impact on work performance, due to the use of sick days by patients in 
the period after diagnosis. This study quantified the effects of prostate cancer on 
indirect costs related to work absence and unemployment among individuals 
age 40 and older. METHODS: Using 1996-2009 data from the Medical Expenditure 
Panel Survey (MEPS), a large, nationally-representative database from the US, we 
performed multivariate analyses evaluating the relationship between prostate 
cancer and indirect costs, at the individual and US aggregate levels. All men with 
International Classification of Disease Codes, ninth revision of 185 were 
identified. Costs by 2 age categories (40-64 years, 65+ years) were explored. 
Indirect costs were defined as lost worker productivity resulting from being 
unemployed or days of missed work as a result of illness. RESULTS: The MEPS 
database included 1,399 patients with prostate cancer. Mean age was 72 years, 
and 71% were Caucasian. Prostate cancer patients had a greater probability of 
being unemployed (40% vs. 34%) and a greater probability of missing work due to 
illness (68% vs. 47%) than non-prostate cancer patients. Employed patients with 
prostate cancer missed 9.3 more work days than individuals without prostate 
cancer (19.5 vs. 10.2). This resulted in an incremental indirect cost of $2936 per 
patient. Indirect costs due to prostate cancer were higher for patients aged 40-64 
than patients aged 65+ ($6848 versus $1581). When aggregated to the  
US population, prostate cancer accounted for $4.21 billion in indirect costs,  
with $2.68 billion for patients aged 40-64 and $1.53 billion for patients aged 65 
and older. CONCLUSIONS: These findings indicate that the indirect cost burden 
from prostate cancer is quite large, especially for younger patients. Further 
research is needed to determine the impact of disease severity on productivity-
related costs.  
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OBJECTIVES: Treatment patterns and cost of care are believed to vary 
substantially as patients with colorectal cancer (CRC) progress from first line 
through third line therapy. The aim of this study was to examine patterns and 
cost of care in these patients. METHODS: A retrospective analysis was performed 
using claims from the Optum Oncology Research Database. Patients aged 18 
years and older, diagnosed with CRC between July 1, 2004 and December 31, 
2010, who were insured by a commercial health plan were included in the study. 
Chemotherapy combinations were assessed for patients receiving first, second 
and third line of therapy for CRC; and for patients with and without metastatic 
disease. Inpatient, outpatient, chemotherapy, biologic-related, and total costs 
were compared by the Kruskal-Wallis test. RESULTS: A total of 1039 patients 
who received chemotherapy or biologic therapy for CRC were included. FOLFOX 
and fluorouracil monotherapy were the most common first-line therapies, each 
accounting for approximately 27% of patients who received any chemotherapy. 
Oxaliplatin-based regimens were most common for patients receiving second-
line therapy (45% of patients). Irinotecan-based regimens were most common 
among patients receiving third line therapy (35% of patients). The median total 
cost of care increased significantly for patients receiving first ($25,782), second 
($36,951), and third ($86,944) line therapy (p<0.0001 by Kruskal-Wallis test). 
Median costs were significantly greater for patients receiving third versus first 
line therapy for outpatient care ($39,952 vs. $15,521), inpatient care ($3,668 vs. 
$1,721 vs.), chemotherapy ($14,059 vs. $3,662) and biologic therapy ($28,824 vs. 
$4,899). Median total were significantly greater for patients with metastases 
($39,001) compared with those without ($8,989; p<0.0001). CONCLUSIONS: 
Treatment patterns vary significantly by line of therapy in patients with CRC. 
The total cost of care increased significantly as patients received additional lines 
of therapy and is significantly greater for patients with metastases compared to 
those without.  
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OBJECTIVES: Carcinoma of kidney (or renal cell carcinoma) is one common 
tumor for adults. The purpose of this study was to evaluate the direct costs of 
patients with carcinoma of kidney in China, producing an average cost per 
patient per year and the overall economic burden of the whole carcinoma of 
kidney population. METHODS: A cost-of-illness analysis was then performed. 
The Chinese Basic Medical Insurance Databases in 2010 were used to collect data 
on health care resource utilization and costs. 224 patients diagnosed with 
carcinoma of kidney were randomly selected by stratified two-stage sampling. 
All information of patient demographic characters, clinical and costs were 
collected for the analysis. Direct medical costs included were diagnostic tests, 
physiotherapy, surgery, drug and administration costs. The descriptive statistics 
was used to describe patients’ demographic characters and costs. Prevalence 
data on carcinoma of kidney for the Chinese population was collected from 
literatures. The overall economic burden of the whole carcinoma of kidney 
population was estimated based on the costs per patient per year and the 
prevalence data. All costs referred to 2010. RESULTS: Total 224 patients (mean 
age 60.9 years; 72.6% male) were evaluated. Total costs per patient over 1 year 
amounted to Chinese Yuan (CNY) 17,366 (median: CNY15750, IQR: CNY7773 –
CNY26285), with drug costs accounting for 50.14% of the total. Based the 
prevalence of carcinoma of kidney from literatures, there was about 74,809 
patients of carcinoma of kidney. Costs for the nation are estimated at CNY 0.389 
billion per year. CONCLUSIONS: The economic burden of carcinoma of kidney in 
China is considerable. The primary burden on patients was due to drugs.  
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OBJECTIVES: This study quantified the “spillover” effects of prostate cancer on 
indirect costs related to work absence and unemployment among spouses and 
other family members residing with prostate cancer patients, a topic that has 
received little attention in the literature. METHODS: Using 1996-2009 data from 
the Medical Expenditure Panel Survey (MEPS), a large, nationally-representative 
database from the US, this study performed multivariate analyses evaluating the 
relationship between prostate cancer and the indirect costs to family members 
and spouses of prostate cancer patients. Indirect costs were defined as lost 
worker productivity resulting from being unemployed or missed work-days as a 
result of prostate cancer. Spillover effects were calculated for all individual 
family members (including spouses) and for spouses separately, and projected to 
the US population. RESULTS: The MEPS database included data for 1,399 patients 
with prostate cancer, 1,121 family members and 874 spouses. Family members of 
prostate cancer patients were found to have incurred $1,319 in annual indirect 
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costs. In the US, the family members’ aggregate productivity loss was estimated 
at $3.3 billion. Spouses of prostate cancer patients were found to have incurred 
$1,309 in lost productivity. Spouses’ aggregate productivity loss was estimated at 
$1.3 billion. Sensitivity analysis of the aggregated US estimates revealed that the 
total lost productivity of family members as a result of prostate cancer ranged 
from $2.2 billion to $4.6 billion. For spouses of prostate cancer patients, the 
results of the sensitivity analysis ranged from $0.9 billion to $1.7 billion. 
CONCLUSIONS: These findings indicate that prostate cancer has a significant 
impact on work productivity of prostate cancer patients’ families and spouses. 
However, there are few resources available to assist prostate cancer patients and 
families in dealing with the disease from a psychosocial aspect. Research is 
warranted to further assess the negative effects of prostate cancer on families.  
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OBJECTIVES: To obtain the standard treatment cost of female breast cancer with 
different TNM Stage. METHODS: The treatment cost of female breast cancer 
consisted of direct medical expenditure, direct non-medical expenditure, and 
indirect expenditure. Extracting previous data, calculating by clinical pathway, 
face-to-face interviewing, and telephone interviewing were adopted to estimate 
the treatment cost of female breast cancer; ANOVA and SNK were performed to 
detect the significantly differences in treatment cost with different TNM stages. 
RESULTS: Direct medical expenditure was extracted from medical record and 
expense statement of 316 breast cancer cases in Sichuan Cancer Hospital; direct 
non-medical expenditure was investigated from 59 patients and their relatives; 
indirect expenditure was surveyed from 94 cases who received surgery more 
than one year ago. The average treatment cost of female breast cancer was 
RMB154,658 (US$24,854), which was adjusted by the proportions of ER, PR, and 
menses status of patients. The range of treatment cost from TNM 0 stage to TNM 
IV stage is RMB37,608-RMB207,824 (US$6,044-US$33,397). Breast cancer cases 
with early stage had considerably lower treatment cost than those with 
advanced stage. CONCLUSIONS: Early detection and treatment of breast cancer 
may have a real economic significance for reducing the burden of disease.  
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OBJECTIVES: Studies have shown that men diagnosed with metastatic prostate 
cancer report significantly reduced quality of life (QoL) and have higher levels of 
depression and anxiety than men with localized prostate cancer. The present 
study assessed the impact of prostate cancer on health-related QoL compared to 
individuals without prostate cancer. METHODS: Using 1996-2009 data from the 
Medical Expenditure Panel Survey (MEPS), multivariate analyses were performed 
on three health status measures: 1) EuroQol EQ-5D, 2) Short Form (SF)-12 Health 
Survey, 3) Self-reported health status. All men age 40 and older with 
International Classification of Disease Codes, 9th revision of 185 were identified. 
RESULTS: The MEPS database included 1,399 patients with prostate cancer. Mean 
age was 72 years, and 71% were Caucasian. The EQ-5D results indicated that QoL 
was 5% lower for prostate cancer patients than individuals without prostate 
cancer (0.76 vs. 0.80, p < 0.001). Results of the SF-12 Physical Health Composite 
Scores (PCS) indicated that prostate cancer patients scored lower than 
individuals without prostate cancer (44.6 vs. 46.3 [population norm = 50],  
p < 0.001). Prostate cancer patients also rated themselves 12% lower on the self-
reported physical health status than individuals without prostate cancer (0.69 vs. 
0.78, p < 0.001). There was no significant difference in mental health of prostate 
cancer patients as measured by the SF-12 Mental Health Composite Score or self-
reported mental health status. CONCLUSIONS: These findings indicate that 
prostate cancer has a significant negative effect on physical health as measured 
by the EQ-5D, the SF-12 PCS, and patient self-report. Prostate cancer had no 
discernible effect on patients’ mental health. Further research on the effects of 
disease severity on QoL is warranted as literature indicates that there are few 
psychosocial interventions for patients with advanced disease.  
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OBJECTIVES: Patients diagnosed with metastatic (M1) prostate cancer (PCa) are 
predisposed to skeletal related events (SREs), including bone surgery (BS), 
pathologic fracture (PF) and spinal cord compression (SCC). There is limited 
information regarding the change in costs associated with SREs, by type, among 
stage IV M1 PCa patients. METHODS: We analyzed patients aged 66+ with an 
(AJCC) M1 PCa diagnosis. Cases diagnosed between 2000 and 2007 were identified 
from the Surveillance, Epidemiology, and End Results (SEER)-Medicare dataset. 
Patients were followed until death or censoring. Incremental costs per patient 
were calculated for the 12-month pre-period and the 12-month post-period 
relative to the first post-diagnosis SRE. Results were reported as the average 
percent change in the total pre-post period costs. Subgroup analysis was carried 
out separately for individuals who survived (survivors) and died (non-survivors) 
within the 12-month post-period. A sensitivity analysis was carried out for a  
6-month pre-post interval. The analysis was conducted from a US Medicare 
system perspective. RESULTS: Application of inclusion criteria resulted in 1,234 
stage IV M1, PCa patients with SREs. The average age was 78 years and 11% were 
African American. Five, mutually exclusive SRE groups were evaluated: PF-only 
(n=180), SCC-only (n=634), BS-only (n=200), PF with BS (n=163), SCC with BS 
(n=57). The average percent increase in the total costs in the post-period 
compared to the pre-period was 67%. The average percent increases in costs for 
each of the subgroups were as follows: PF-only, 53%; PF with BS, 71%; SCC-only, 
64%; SCC with BS, 88%; and BS-only, 70%. Subgroup analysis showed a 77% 
increase in total costs among survivors and a 60% increase in costs among non-
survivors. The average percent increase in SRE costs using a pre-post period of 6 
months was 75%. CONCLUSIONS: The percentage increase in costs post-SRE 
varies by type of SRE, survival post-SRE, and interval length.  
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OBJECTIVES: Costs for the population of metastatic castrate-resistant prostate 
cancer (mCRPC) patients can be difficult to discern due to the lack of a specific 
International Classification of Diseases, 9th Revision (ICD-9) code. This study 
described the resource utilization and costs of patients with mCRPC in a large US 
health claims database using chemotherapy administration as a proxy. 
METHODS: Data from January 1, 2006-June 30, 2011 from the MarketScan 
Commercial and Medicare databases were used in this analysis. Index date was 
defined as the first docetaxel, mitoxantrone, estramustine, vinorelbine, 
cabazitaxel or abiraterone treatment date between January 1, 2007 and June 30, 
2010. Additional inclusion criteria: >=18 years old; continuous pharmaceutical 
and medical enrollment >=6 months prior to and >=2 months following the index 
date; >=1 ICD-9 diagnosis code for prostate cancer (185.x). mCRPC related costs 
were identified by the presence of an ICD-9 code of 185.x on the claim. Costs 
were estimated separately for chemotherapy, radiation, inpatient, outpatient 
and emergency room (ER). Median per patient per month (PPPM) costs were 
calculated at the patient level. RESULTS: 4,005 patients were eligible, with a 
mean age of 70.2 years. For patients with medical utilization, total median PPPM 
costs increased from $3,107 pre-index to $6,939 post-index. Chemotherapy costs 
increased ($234 pre-index vs. $1,439 post-index), while radiation costs decreased 
($793 vs. $394). Excluding costs related to chemotherapy, radiation and other 
drug treatment, costs for inpatient, outpatient and ER visits increased from 
$2,120 pre-index to $4,388 post-index. Both mCRPC-related costs ($862 vs. $1,986) 
and non-mCRPC-related costs ($763 vs. $1,628) rose. CONCLUSIONS: These 
findings indicate that the cost burden from mCRPC is quite large. With aging of 
the population, prevalence of prostate cancer is expected to increase to 3.2 
million in the US by 2020 with costs continuing to escalate. Further research is 
needed to understand these cost implications, especially for the Medicare 
system.  
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OBJECTIVES: To assess the clinical burden, health care utilization, and cost 
patterns of prostate cancer patients in the U.S. veteran population. METHODS: A 
retrospective database analysis was performed using the Veterans Health 
Administration (VHA) Medical SAS Datasets from October 1, 2005 to May 31, 2012. 
All U.S. veteran beneficiaries diagnosed with prostate cancer were identified 
using International Classification of Disease 9th Revision Clinical Modification 
(ICD-9-CM) diagnosis code 185.xx. Descriptive statistics were calculated as 
means ± standard deviation (SD) and percentages to measure clinical, cost, and 
utilization distribution in the sample. The most common comorbidities and 
treatment medications for prostate cancer patients were also examined. 
RESULTS: Among all study patients diagnosed with prostate cancer (n=251,890), 
the most common comorbidities were hypertension (n=69,534, 27.60%), elevated 
prostate-specific antigen (PSA) levels (n=45,498, 18.06%), and diabetes (n=34,171, 
13.57%). The most common treatment medications prescribed for prostate 
cancer patients were simvastatin (n=71,263, 28.29%), omeprazole (n=34,185, 
13.57%) and terazosin hydrochloride (n=22,639, 8.99%). A total of 117,599 (46.69%) 
patients had PSA test results, with an average result of 14.26. Percentages of 
inpatient (12.89%), emergency room (ER) (13.12%), physician office (99.86%), 
outpatient visits (99.87%), and pharmacy visits (90.34%) were calculated. Patient 
expenditures were found to be $4,227 (SD=$28,254) for inpatient, $146 (SD=$582) 
for ER, $6,469 (SD=$11,387) for physician office, $6,781 (SD=$11,837) for outpatient 
visits and $1,247 (SD=$4,159) for pharmacy visits. CONCLUSIONS: PSA laboratory 
test results should be considered when evaluating disease severity and 
progression of prostate cancer. However, the effects of prescribed medications 
on those test results should always be considered when interpreting laboratory 
results.  
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